Physician profile
Sara Klein
NPI 1831620129
$3,741.90
in general payments reported to CMS, 2019-2025
16 companies · $464 in 2025
The $464 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $280 · 2021: $214 · 2022: $545 · 2023: $654 · 2024: $725 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263 · Education: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.68 |
| Education | $579.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $1,031.23 | 2019-2024 | Ultomiris, Soliris |
| Genzyme Corporation | $598.18 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $402.13 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $309.29 | 2022-2025 | Zeposia |
| Genentech USA, INC. | $235.64 | 2019-2022 | |
| Celgene Corporation | $216.88 | 2023-2025 | Zeposia |
| Emd Serono, INC. | $192.61 | 2020-2023 | Mavenclad |
| Horizon Therapeutics Plc | $174.33 | 2021-2022 | |
| Biogen, INC. | $143.74 | 2020-2025 | Leqembi |
| Pfizer INC. | $124.97 | 2025 | |
| Corium, LLC | $121.84 | 2023 | Adlarity |
| Eisai INC. | $96.16 | 2025 | |
| Averitas Pharma INC. | $34.63 | 2025 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $24.79 | 2025 | Rexulti |
| Daiichi Sankyo INC. | $20.86 | 2024 | Enhertu |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.62 | 2025 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.